Abstract
We developed a pyrazinamidase gene DNA-sequencing method to rapidly identify pyrazinamide resistance-causing mutations in GenoLyse-treated, smear-positive sputum specimens. The sensitivity and specificity were 90.9 and 100%, respectively, compared to those of MGIT drug susceptibility testing, after the exclusion of synonymous mutations and nonsynonymous mutations previously associated with susceptibility to pyrazinamide.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.
Publication types
-
Evaluation Study
-
Research Support, N.I.H., Extramural
MeSH terms
-
Amidohydrolases / genetics*
-
Antitubercular Agents / pharmacology
-
Drug Resistance, Bacterial*
-
Genotype
-
Genotyping Techniques / methods*
-
Humans
-
Microbial Sensitivity Tests / methods
-
Mutation
-
Mycobacterium tuberculosis / drug effects
-
Mycobacterium tuberculosis / genetics*
-
Pyrazinamide / pharmacology
-
Sensitivity and Specificity
-
Sequence Analysis, DNA / methods*
-
Time Factors
Substances
-
Antitubercular Agents
-
Pyrazinamide
-
Amidohydrolases
-
PncA protein, Mycobacterium tuberculosis